Stock Ratings | Mizuho raised its price target for SanDisk (SNDK) to $1,825; Lake Street initiated coverage of Aligos (ALGS) with a buy rating and a price target of $45, implying a potential gain of 677.2%.
ARS Pharmaceuticals, Inc. SPRY | 0.00 | |
Precigen Inc PGEN | 0.00 | |
HCW Biologics, Inc. HCWB | 0.00 | |
Aligos Therapeutics, Inc. ALGS | 0.00 | |
MediWound Ltd. MDWD | 0.00 |
The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.
Risk warning:
Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.
Today's key assessments and concerns
Cantor Fitzgerald: Maintaining an "overweight" rating on ARS Pharmaceuticals ( ARS Pharmaceuticals, Inc.(SPRY.US) ), while raising the price target from $12 to $30.
HC Wainwright & Co.: Maintaining a "buy" rating on Precigen ( Precigen Inc(PGEN.US) ), with a price target raised from $11 to $14.
Maxim Group: Maintaining a "buy" rating on HCW Biologics ( HCW Biologics, Inc.(HCWB.US) ), while raising the price target from $2 to $5.
Lake Street: Initial rating for Aligos Therapeutics ( Aligos Therapeutics, Inc.(ALGS.US) ) at "Buy", with a target price of $45.
Oppenheimer: Maintaining an "outperform" rating for MediWound ( MediWound Ltd.(MDWD.US) ), while lowering the price target from $33 to $32.
| The symbol | Classification | Target price | Current price | Percentage of potential increase/decrease | (Classification) Agency |
| ARS Pharmaceuticals, Inc.(SPRY.US) | to lift | $30.0 | $9.4 | 219.15% | Cantor Fitzgerald |
| Precigen Inc(PGEN.US) | to lift | $14.0 | $4.51 | 210.42% | HC Wainwright & Co. |
| HCW Biologics, Inc.(HCWB.US) | to lift | $5.0 | $2.09 | 139.23% | Maxim Group |
| Equillium(EQ.US) | to lift | $6.0 | $2.84 | 111.27% | Leerink Partners |
| Corcept Therapeutics Incorporated.(CORT.US) | to lift | $135.0 | $68.38 | 97.43% | Canaccord Genuity |
| Aligos Therapeutics, Inc.(ALGS.US) | Initial classification | $45.0 | $5.79 | 677.2% | Lake Street |
| MediWound Ltd.(MDWD.US) | cut | $32.0 | $14.56 | 119.78% | Oppenheimer |
| Boston Scientific Corporation(BSX.US) | cut | $89.0 | $49.11 | 81.23% | Barclays |
| Phreesia(PHR.US) | cut | $16.0 | $9.45 | 69.31% | Canaccord Genuity |
| Abercrombie & Fitch Co. Class A(ANF.US) | cut | $136.0 | $82.18 | 65.49% | UBS |
comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)
Lifting
Mizuho: Maintaining its "outperform" rating for Arm Holdings ( Arm Holdings(ARM.US) ), while raising its price target from $290 to $360.
Susquehanna: Maintaining a "positive" rating on Broadcom Limited(AVGO.US) ) stock, while raising the price target from $450 to $490.
B. Riley Securities: Maintaining a "buy" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ), while raising the price target from $205 to $240.
Mizuho: Maintaining Dell Dell Technologies, Inc. Class C(DELL.US) rating at "Outperforming the Market," while raising the price target from $300 to $350.
Cantor Fitzgerald: Maintaining an "overweight" rating on IREN Limited ( IREN Limited(IREN.US) ), while raising the price target from $77 to $99
Morgan Stanley: Maintaining a "Market-Similar Weight" rating for Marvell Technology ( Marvell Technology, Inc.(MRVL.US) ), while raising the price target from $172 to $195.
DA Davidson: Maintaining a "buy" rating on Micron Technology Micron Technology, Inc.(MU.US) , raising the price target from $1,000 to $1,500.
Mizuho: Maintaining Micron Technology's Micron Technology, Inc.(MU.US) ) rating at "Outperform Market", while raising the price target from $800 to $1150.
Mizuho: Maintaining SanDisk's ( Sandisk Corporation(SNDK.US) ) rating at "Outperforming the Market," while raising the price target from $1625 to $1825.
UBS: Maintaining a "buy" rating on Snowflake Snowflake(SNOW.US) , while raising the price target from $210 to $325.
Bernstein: Maintaining its rating on Snowflake Snowflake(SNOW.US) ) stock at "Market Match," while raising its price target from $195 to $250.
First Coverage
Oppenheimer: Initial rating for Adlai Nortye ( Adlai Nortye Ltd. Sponsored ADR(ANL.US) ) at "outperforms the market", with a price target of $32.
Oppenheimer: Initial rating for Granite Construction ( Granite Construction Incorporated(GVA.US) ) at "outperforms the market", with a price target of $170.
Barclays: Sutro Biopharma ( Sutro Biopharma, Inc.(STRO.US) ) initial rating at "overweight", with a price target of $56
reduction
Macquarie: Maintaining a "neutral" rating on Salesforce ( Salesforce.com, inc.(CRM.US) ) stock, while lowering the price target from $200 to $190.
Piper Sandler: Confirming the rating on Nutanix Nutanix(NTNX.US) ) stock at "overweight", with a price target cut from $63 to $60.
Barclays: Downgraded PDD ( PINDUODUO INC.(PDD.US) ) stock to "market equivalent weight," with a price target cut from $165 to $89.
UBS: Verra Mobility ( Verra Mobility Corp. Class A(VRRM.US) ) lowered its rating to "neutral," cutting its price target from $23 to $4.
Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.